[Federal Register Volume 69, Number 17 (Tuesday, January 27, 2004)]
[Notices]
[Page 3947]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-1652]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec. 1301.33(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on October 27, 2003, Novartis 
Pharmaceutical Corporation, Attn: Security Department, Building 103, 
Room 335, 59 Route 10, East Hanover, New Jersey 07936, made application 
by renewal to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of Methylphenidate (1724), a basic 
class of Schedule II controlled substance.
    The firm plans to produce bulk product and finished dosage units 
for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than March 29, 
2004.

    Dated: December 24, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-1652 Filed 1-26-04; 8:45 am]
BILLING CODE 4410-09-M